US · WOK · MEDICAL - SPECIALTIES
WORK Medical Technology Group Ltd. Class A (WOK) intrinsic value and stock valuation
$1.10as of 2026-11-21 · Mkt cap 5.13M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
WORK Medical Technology Group Ltd. Class A DCF and intrinsic value
InvestorsCraft values WOK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from WOK’s statements →
WORK Medical Technology Group Ltd. Class A Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.85M | $11.5M | $13.6M | $19.7M | $45.9M |
| Operating income | -$-2.5M | -$-3.7M | $490K | $1.82M | $7.67M |
| Net income | -$-1.07M | -$-3.49M | $110K | $870K | $5.96M |
| EPSd | -$-3.69M | -$-26.85M | $916.7K | $7.25M | $49.7M |
| Operating cash flow | $6.24M | -$-2.23M | $2.21M | -$-2.26M | -$-7.18M |
| Capital expenditure | -$-1.33M | -$-9.26M | -$-580K | -$-2.01M | -$-60K |
| Free cash flow | $4.91M | -$-11.49M | $1.63M | -$-4.27M | -$-7.24M |
| Total assets | $33.2M | $36.3M | $30M | $25.5M | $30.7M |
| Total debt | $6.45M | $13.5M | $9.1M | $6.3M | $6.6M |
| Net debt | $2.36M | $6.91M | $7.5M | $5.57M | $6.09M |
| Total equity | $21.2M | $16.1M | $11M | $11.2M | $11.4M |
| Cash and short-term investments | $4.09M | $6.56M | $1.6M | $730K | $510K |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.85M | $11.5M | $13.6M | $19.7M | $45.9M |
| Cost of revenue | $7.5M | $8.64M | $9.42M | $15.3M | $37.2M |
| Gross profit | $2.34M | $2.87M | $4.14M | $4.42M | $8.64M |
| Research and development expenses | $440K | $300K | $300K | $180K | $190K |
| Selling, general and administrative expenses | $4.41M | $6.61M | $3.43M | $3.6M | $4.49M |
| Other expenses | $0.00 | -$-350K | -$-70K | -$-1.19M | -$-3.71M |
| Operating expenses | $4.84M | $6.57M | $3.66M | $2.59M | $970K |
| Cost and expenses | $12.3M | $15.2M | $13.1M | $17.9M | $38.2M |
| Interest income | $180K | $10K | $0.00 | $0.00 | $0.00 |
| Interest expense | $500K | $560K | $370K | $350K | $330K |
| Depreciation and amortization | $920K | $1.39M | $1.6M | $3.26M | $4.19M |
| Ebitda | $340K | -$-1.71M | $2.08M | $4.72M | $11.9M |
| Operating income | -$-2.5M | -$-3.7M | $490K | $1.82M | $7.67M |
| Total other income/expenses, net | $1.41M | $380K | -$-380K | $480K | $3.38M |
| Income before tax | -$-1.08M | -$-3.67M | $110K | $1.11M | $7.34M |
| Income tax expense | $120K | -$-130K | $50K | $170K | $1.08M |
| Net income | -$-1.07M | -$-3.49M | $110K | $870K | $5.96M |
| Weighted average shares outstanding | $290K | $130K | $130K | $130K | $130K |
| Weighted average diluted shares outstanding | $290K | $130K | $120K | $120K | $120K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.09M | $6.56M | $1.6M | $730K | $510K |
| Net receivables | $12.5M | $5.75M | $11M | $6.15M | $6.57M |
| Inventory | $3.68M | $3.18M | $4.62M | $4.36M | $6.29M |
| Total current assets | $20.5M | $20.8M | $22.2M | $16.6M | $18.2M |
| Property, plant and equipment, net | $10.6M | $14.3M | $6.74M | $7.98M | $11.5M |
| Goodwill and intangible assets | $960K | $1.04M | $1M | $950K | $1.06M |
| Long-term investments | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $12.7M | $15.4M | $7.81M | $8.93M | $12.5M |
| Total assets | $33.2M | $36.3M | $30M | $25.5M | $30.7M |
| Accounts payable | $1.72M | $1.5M | $3.96M | $3.2M | $9.04M |
| Short-term debt | $6.41M | $13.5M | $9.05M | $6.23M | $6.6M |
| Deferred revenue | $400K | $630K | $780K | $740K | $1.59M |
| Total current liabilities | $12M | $20.2M | $18.9M | $14.3M | $18.9M |
| Long-term debt | $40K | $0.00 | $50K | $70K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $20K | $140K | $50K | $90K | $350K |
| Capital lease obligations | $20K | $0.00 | $100K | $90K | $0.00 |
| Total liabilities | $12M | $20.2M | $19M | $14.4M | $19.3M |
| Common stock | $50K | $10K | $10K | $10K | $50K |
| Retained earnings | $4.96M | $6.08M | $9.58M | $9.51M | $8.74M |
| Accumulated other comprehensive income (loss) | $290K | $490K | $210K | $410K | $1.21M |
| Total equity | $21.2M | $16.1M | $11M | $11.2M | $11.4M |
| Total investments | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.45M | $13.5M | $9.1M | $6.3M | $6.6M |
| Net debt | $2.36M | $6.91M | $7.5M | $5.57M | $6.09M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.07M | -$-3.49M | $60K | $940K | $6.27M |
| Depreciation and amortization | $920K | $1.39M | $1.6M | $3.26M | $4.19M |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | $6.44M | -$-110K | $460K | -$-7.13M | -$-18.16M |
| Accounts receivable | $1.02M | $1.82M | -$-130K | -$-3.96M | -$-120K |
| Inventory | $570K | $1.58M | -$-400K | $2.05M | $6.89M |
| Accounts payable | $250K | -$-2.55M | $860K | -$-5.82M | -$-2.94M |
| Net cash provided by operating activities | $6.24M | -$-2.23M | $2.21M | -$-2.26M | -$-7.18M |
| Investments in property, plant and equipment | -$-1.33M | -$-9.23M | -$-460K | -$-2.01M | -$-60K |
| Acquisitions, net | $390K | $0.00 | $0.00 | $60K | $0.00 |
| Net cash used for investing activities | -$-7.61M | -$-9.06M | -$-580K | -$-1.35M | -$-60K |
| Common stock issued | $6.9M | $7.37M | $0.00 | $0.00 | $790K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-900K | $15.7M | -$-730K | $3.57M | $7.99M |
| Net change in cash | -$-2.87M | $4.92M | $860K | -$-100K | $670K |
| Cash at end of period | $4.09M | $6.56M | $1.64M | $770K | $870K |
| Operating cash flow | $6.24M | -$-2.23M | $2.21M | -$-2.26M | -$-7.18M |
| Capital expenditure | -$-1.33M | -$-9.26M | -$-580K | -$-2.01M | -$-60K |
| Free cash flow | $4.91M | -$-11.49M | $1.63M | -$-4.27M | -$-7.24M |
Line items
Line items
Line items
About WORK Medical Technology Group Ltd. Class A
WORK Medical Technology Group LTD, through with its subsidiaries, manufactures and sells medical consumables and devices in the People's Republic of China and internationally. The company offers medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, yankauer suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half masks; visualized prostatic dilatation catheters; and nebulizer kits, SPO2 sensors, nasogastric tubes, personal protective equipment, hygiene and skincare products, cleaners for household use, and non-powered air-purifying particle respirators. It also engages in the research and development of biological and medical technology; and sale of chemical products. The company serves hospitals, pharmacies, and medical institutions. It exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.
- CEO
- Shuang Wu
- Employees
- 238
- Beta
- 1.74
Explore
Frequently asked questions
What is the intrinsic value of WORK Medical Technology Group Ltd. Class A (WOK)?
InvestorsCraft does not currently publish an intrinsic value for WOK. How the IC value is calculated.
Is WOK undervalued?
InvestorsCraft does not publish an undervaluation signal for WOK at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.